F3 and Sepsis: It is noteworthy that the four largest clinical studies evaluating novel therapies in patients with sepsis – evaluating drotrecogin alpha, tissue factor pathway inhibitor, antithrombin III, and monoclonal antibodies to TNF [27-30] – did not specify hemodynamic goals.